Acute and subchronic effects of the H1-histamine receptor antagonist ebastine in 10, 20 and 30 mg dose, and triprolidine 10 mg on car driving performance.
1. The effects of a new antihistamine, ebastine (10, 20 and 30 mg), on several parameters of driving performance in actual traffic were studied in 15 healthy male volunteers. Subjects were treated for 5 days, and their driving performance tested on day 1 and day 5. The study was double-blind, placebo controlled and included the antihistamine triprolidine (10 mg sustained release) as an active drug control. 2. General tolerability was good except in one case following the reference compound triprolidine. No significant changes in driving performance were found with the new antihistamine ebastine at any dosage, on day 1 or day 5. Triprolidine (10 mg) significantly increased both the amount of weaving and the delay in following speed manoeuvres of a leading car, compared with placebo. 3. The results suggest that ebastine in doses up to 30 mg may be relatively safe for use by those who drive motor vehicles while under medication. The results do not warrant such a conclusion for triprolidine 10 mg.
Brookhuis
K A
KA
Traffic Research Centre, University of Groningen, Haren, The Netherlands.
De Vries
G
G
De Waard
D
D
D000328:Adult; D001334:Automobile Driving; D002090:Butyrophenones / Q000097:blood / Q000494:pharmacology*; D004311:Double-Blind Method; D006634:Histamine H1 Antagonists / Q000097:blood / Q000494:pharmacology*; D006801:Humans; D008297:Male; D010880:Piperidines / Q000097:blood / Q000494:pharmacology*; D011597:Psychomotor Performance / Q000187:drug effects; D014311:Triprolidine / Q000097:blood / Q000494:pharmacology*
D002090:Butyrophenones; D006634:Histamine H1 Antagonists; D010880:Piperidines; D014311:Triprolidine; C058249:ebastine